Ablexis delivers a transgenic mouse platform for the discovery of therapeutic antibodies.

Ablexis

Ablexis, LLC | 499 followers on LinkedIn. A superior, next generation transgenic platform. | Ablexis offers the AlivaMab® Mouse platform, a suite of transgenic mouse strains for human therapeutic antibody discovery. AlivaMab Mouse strains are uniquely designed to be better for human therapeutic antibody discovery and development, for applications across antibody drug discovery including highest quality IgGs, singe-domain VH, multispecifics, ADCs, CARs, TCRm, and other modalities.  The AlivaMab Mouse strains are well-documented for generating drug-like antibodies with broad combinatorial and somatic diversities, high affinities, specificity, and excellent developability properties.

Ablexis, LLC

Thanks, Ian Wilkinson, for adding to the conversation about the importance of human Ig lambda light chains. I wholeheartedly agree about lambda light chains being important for engaging certain epitopes, either altogether or with sufficient affinity to meet potency requirements. I have 20+ years of accumulated anecdotal evidence, first using XenoMouse(R) Mice and now using AlivaMab(R) Mice.

From the 2014 generation 1 of AlivaMab Mouse to the generation 6 versions now being launched, we recognized the importance of including a well-functioning human Ig lambda light chain locus to maximize probability of success in antibody drug discovery. Our partners have benefited from that foresight. Talk to us to learn about the benefits of other unique design features incorporated into the AlivaMab Mouse strains that make them the best platform choice for antibody drug discovery.

Last year's Innovation Day was inspiring and a lot of fun. Meet us in San Diego at Innovation Day 2024 - it will be even better!

Jane always does a fantastic job in leading discussions and moderating panels. This will be a "can't miss" session!

Join the team at AlivaMab Biologics and help discover the next great biologic drug to improve patients' outcomes!

Don't miss this roundtable! Jane will do a great job in leading a scintillating discussion and debate.

Ablexis and AlivaMab Biologics celebrate our ten years of innovations in antibody drug discovery, commencing in 2014 with launch of the 1st generation AlivaMab® Mouse strains and continuing onward with our launching of the 6th generation AlivaMab Mouse strains, used in synergy with the innovative high-throughput discovery and engineering platforms of AlivaMab Biologics. The patented AlivaMab Mouse technology remains a platform differentiated from other transgenic animals and in vitro display technologies, providing superior performance and efficiency in antibody discovery while risk-mitigating downstream development. Our most recent innovations include the AlivaMab Mouse-XKL strains, demonstrated to produce even greater combinatorial diversity in the IgG repertoire, and AlivaMab Mouse-SD, for the discovery of single-domain human VH antibodies. For common light chain antibody discovery, AlivaMab Biologics offers its unique platform that combines the best of in vivo, in vitro, and NGS-based discovery. To learn more about why AlivaMab Mouse and AlivaMab Biologics provide the best platforms for biologics drug discovery and engineering, contact us at info@alivamab.com or info@ablexis.com .

Thank you to the many people with whom we met at East Coast Antibody HubXChange! Lots of follow-ups!

Another AlivaMab antibody achieves an important clinical milestone!

Come meet with us next week in Woburn, MA at East Coast Antibody HubXChange. Jane will be presenting beautiful data about creating, interrogating, and capturing incredible antibody diversity for superior biologics drug discovery.

Viewport Meta

IPhone / Mobile Compatible

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

Google Font API

Google Analytics

WordPress

Global Site Tag

LetsEncrypt

Chief Executive Officer

Larry Green

Store Owner

Beau Franklin

Scott Greer

Cary Pfeffer

Lou Tartaglia

Hiroaki Shizuya

Founder

Western US Acquired Companies With Less Than $1B in Revenue

San Francisco Companies (Top 10K)

West Coast Acquired Companies With Fewer Than 50 Employees

United States Health Care Acquired Companies

Ablexis, LLC, a biotechnology company dedicated to developing an innovative, next-generation platform for antibody drug discovery, was founded in December 2009, based on technology principles established by its subsidiary, Aliva Biopharmaceuticals, Inc.

Third Rock Ventures

Series A - Ablexis

San Francisco

California

United States

North America

AlivaMab Biologics Announces Two Bispecific Antibody ...

AlivaMab Discovery Services Changes Name to AlivaMab ...

Ablexis Announces License Agreement with Adimab

Ablexis and AlivaMab Discovery Services Announce Expansio...

Ablexis and AlivaMab Discovery Services Announce Agreements with Almirall to Accelerate Antibody Drug Discovery and Development

Ablexis Announces Multi-Target License Agreement with Tanabe Research Laboratories U.S.A.

Ablexis Announces Further Expansion of Its Intellectual Property on AlivaMab® Mouse and Immunoglobulin Locus Engineering

AlivaMab Discovery Services Announces Planned Leadership Transition

Ablexis Targets Market Expansion Opportunities for AlivaMab Mouse Following Acquisition by Deerfield Management and the Founding of AlivaMab Discovery Services

A transgenic mouse platform designed for the discovery of human therapeutic antibodies, featuring synthetic immunoglobulin transgenes and a curated repertoire of gene segments.

New strains of AlivaMab mice that expand the molecular and epitope diversity of the immune response for broader antibody discovery.

Services provided by AlivaMab Discovery Services, including the generation and delivery of therapeutic antibody candidates using the AlivaMab Mouse platform.

Next-generation sequencing-based capabilities to expand the diversity of captured antibodies beyond traditional hybridoma approaches.

Technology to enhance the capture of diverse immune responses, aiding in downstream screening and antibody engineering.

Non-exclusive licensing models for the AlivaMab Mouse platform, including renewable annual, individual target, and perpetual licenses.

news impact assignment basic	general
public peers	general	Nov 17, 2024 8:46 PM	a23ecc26
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 17, 2024 8:46 PM	8b23d17f
crunchbase trigger	general	Nov 17, 2024 8:46 PM	ca9c0086
crunchbase profile	general	Nov 17, 2024 9:05 PM	7c67a5c5
li profile	general	Nov 17, 2024 8:46 PM	246e3e6a
translate crunchbase fundingrounds	general	Nov 17, 2024 9:30 PM	7e3d1d72
peers	general	Nov 17, 2024 8:46 PM	5181bb8e
news basic	general	Nov 17, 2024 8:46 PM	32f4a7d7
bundesanzeiger	filings
financials download nd	financials
private financials	financials

ABLE

COM:ABLEXIS

Ablexis